Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
Virendra Rambiritch,1 Poobalan Naidoo,2 Goonaseelan Pillai3 1Pharmacology Department, University of KwaZulu-Natal, Durban, 2Department of Internal Medicine, RK Khan Regional Hospital, Chatsworth, South Africa; 3Scientific Capability Development, Novartis Pharma AG, Basel, Switzerland Aim: To determi...
Guardado en:
Autores principales: | Rambiritch V, Naidoo P, Pillai G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ef245e3baff44c9da0e8c9768f2374d2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
por: Rambiritch V, et al.
Publicado: (2016) -
Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan
por: Muhammad Muaaz Munir, et al.
Publicado: (2021) -
Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost C, et al.
Publicado: (2018) -
Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study
por: Yi Tao, et al.
Publicado: (2021) -
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
por: Andreas Port, et al.
Publicado: (2021)